Skip to content
Screener

Amphastar Pharmaceuticals AMPH Total Equity

Discontinued — last reported Q4 '21

Total Equity at other companies

Pfizer logo
PfizerPFE
$90.1B-0.3%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$143.54M-56.9%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$341.4M-36.3%
Viatris logo
ViatrisVTRS
$14.26B-8.4%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$34.05M+44.1%
Opko Health logo
Opko HealthOPK
$1.18B-8.7%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$873.48M-28.0%
Enterprise value$1.34B-20.6%
P/E11.1×+2.1×
P/S1.2×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Amphastar Pharmaceuticals’s 10-K, filed March 11, 2022. Open the filing →

Filed
Mar 11, 2022, 4:13 PM EST
Fiscal year
FY2021
Accession
0001297184-22-000007

FAQ

What is Amphastar Pharmaceuticals's total equity?
Amphastar Pharmaceuticals (AMPH) reported total equity of $445.52M in Q4 2021.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Amphastar Pharmaceuticals's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude